Our study’s primary finding reveals a distinctive autoimmune profile in patients with RRMS, characterized by significantly elevated IgA, IgM, and IgG antibodies levels targeting key myelin proteins. Here, CD79A is linked to relapsing-remitting multiple sclerosis.